BNGONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Bionano Genomics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.22−0.03 (-2.40%)
Close on Oct 19, 2026
- Market cap
- $14.09M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
6.0%
1M of 12M shares
Institutional holders
33
8 new, 6 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $9.72K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B | 528,245 | 9.99% | 13G (passive) | Sep 30, 2025 |
| Lincoln Alternative Strategies LLC | 525,000 | 5.42% | 13G (passive) | Sep 17, 2025 |
| Lind Global Partners III LLC | 514,338 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| CVI Investments, Inc. | 1,307,135 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Easton Jeff | 1,050,000 | 9.35% | 13G (passive) amendment | Dec 31, 2025 |
| Heights Capital Management, Inc. | 1,021,671 | 9.90% | 13G (passive) | Sep 16, 2025 |
| Jeff Easton | 1,005,961 | 9.90% | 13G (passive) | Sep 17, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BNGO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Gsa Capital Partners Llp | 150,284 | 1.28% | $170 | −203,079 | 0.01% |
| Carret Asset Management, LLC | 125,000 | 1.06% | $141.25K | +55,000 | 0.01% |
| Geode Capital Management, LLC | 89,993 | 0.76% | $101.69K | −77,540 | 0.00% |
| Vanguard Capital Management LLC | 82,388 | 0.70% | $93.10K | +14,279 | 0.00% |
| Vanguard Fiduciary Trust Co | 51,578 | 0.44% | $58.28K | – | 0.00% |
| Renaissance Technologies LLC | 51,100 | 0.43% | $57.74K | +2,400 | 0.00% |
| Jane Street Group, LLC | 35,728 | 0.30% | $40.37K | New | 0.00% |
| Prudential Financial Inc | 31,600 | 0.27% | $35.71K | +3,600 | 0.00% |
| Northern Trust Corp | 24,561 | 0.21% | $27.75K | +4,042 | 0.00% |
| XTX Topco Ltd | 16,295 | 0.14% | $18.41K | New | 0.00% |
| Engineers Gate Manager LP | 11,988 | 0.10% | $13.55K | +135 | 0.00% |
| Hrt Financial LP | 11,740 | 0.10% | $13 | New | 0.00% |
| BlackRock, Inc. | 9,937 | 0.08% | $11.23K | – | 0.00% |
| Osaic Holdings, Inc. | 7,809 | 0.07% | $8.82K | +1,007 | 0.00% |
| Tower Research Capital LLC (TRC) | 5,228 | 0.04% | $5.91K | New | 0.00% |
| Morgan Stanley | 1,037 | 0.01% | $1.17K | +110 | 0.00% |
| Concord Wealth Partners | 1,000 | 0.01% | $1.13K | New | 0.00% |
| Group One Trading, L.P. | 957 | 0.01% | $1.08K | – | 0.00% |
| UBS Group AG | 812 | 0.01% | $918 | +796 | 0.00% |
| SBI Securities Co., Ltd. | 246 | 0.00% | $278 | +12 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 33 | 1M | 6.0% | 8 / 11 | 2 / 6 | 0M | 0M |
| Q1 2026 | 31 | 1M | 7.4% | 9 / 9 | 4 / 8 | 0M | 0M |
| Q4 2025 | 31 | 1M | 7.5% | 9 / 5 | 9 / 8 | 1M | 0M |
| Q3 2025 | 31 | 0M | 2.1% | 8 / 6 | 7 / 5 | 0M | 0M |
| Q2 2025 | 28 | 0M | 0.9% | 5 / 7 | 6 / 6 | 0M | 0M |
| Q1 2025 | 30 | 0M | 0.9% | 28 / 1 | 0 / 3 | 0M | 0M |
| Q4 2024 | 5 | 0M | 0.0% | 5 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BNGO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 113,564 | 0.96% | $140.82K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 82,388 | 0.70% | $93.10K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 11,470 | 0.10% | $14.22K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,769 | 0.02% | $3.43K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Albert Luderer | Interim Chief Executive, Director | 8,000 | 0.07% | Sep 9, 2026 |
| R. Erik Holmlin | PRESIDENT AND CEO, Director | 1,665 | 0.01% | Feb 18, 2026 |
| Jonathan V. Dixon | General Counsel | 239 | 0.00% | Aug 5, 2026 |
| Mark Adamchak | Principal Accounting Officer | 253 | 0.00% | Aug 5, 2026 |
| Alex Reid Hastie | Chief Scientific Officer | 63 | 0.00% | Aug 5, 2026 |
| Mark Oldakowski | Chief Operating Officer | 868 | 0.01% | Aug 5, 2026 |
| Alka Chaubey | CHIEF MEDICAL OFFICER | 620 | 0.01% | Jun 3, 2026 |
| Aleksandar Rajkovic | Director | 0 | – | May 14, 2026 |
| Kristiina Vuori MD | Director | 0 | – | May 14, 2026 |
| Christopher J. Twomey | Director | 74,500 | 0.63% | May 14, 2026 |
| David L. Barker | Director | 58,364 | 0.50% | May 14, 2026 |
| Yvonne Linney | Director | 0 | – | May 14, 2026 |
| Hannah Mamuszka | Director | 65,789 | 0.56% | Jun 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Albert Luderer Interim Chief Executive, Director | Sep 4, 2026 | Buy | +4,000 | $1.21 | $4.84K | 8,000 |
| Albert Luderer Interim Chief Executive, Director | Aug 21, 2026 | Buy | +4,000 | $1.22 | $4.88K | 4,000 |
| Alka Chaubey CHIEF MEDICAL OFFICER | Jun 3, 2026 | Tax withholding | −24 | $1.30 | $31 | 620 |
| Mark Adamchak Principal Accounting Officer | Jun 3, 2026 | Tax withholding | −7 | $1.30 | $9 | 253 |
| Jonathan V. Dixon GENERAL COUNSEL | Jun 3, 2026 | Tax withholding | −24 | $1.30 | $31 | 239 |
| Mark Oldakowski CHIEF OPERATING OFFICER | Jun 3, 2026 | Tax withholding | −27 | $1.30 | $35 | 868 |
| Alka Chaubey CHIEF MEDICAL OFFICER | Feb 17, 2026 | Tax withholding | −18 | $1.10 | $20 | 644 |
| Mark Oldakowski CHIEF OPERATING OFFICER | Feb 17, 2026 | Tax withholding | −20 | $1.10 | $22 | 895 |
| Mark Adamchak Principal Accounting Officer | Feb 17, 2026 | Tax withholding | −3 | $1.10 | $3 | 260 |
| R. Erik Holmlin PRESIDENT AND CEO, Director | Feb 17, 2026 | Tax withholding | −51 | $1.10 | $56 | 1,657 |
| Jonathan V. Dixon GENERAL COUNSEL | Feb 17, 2026 | Tax withholding | −6 | $1.10 | $7 | 263 |
| Mark Oldakowski Chief Operating Officer | Sep 11, 2025 | Tax withholding | −59 | $4.06 | $240 | 915 |
| Alka Chaubey Chief Medical Officer | Sep 11, 2025 | Tax withholding | −51 | $4.06 | $207 | 662 |
| Mark Oldakowski Chief Operating Officer | Sep 11, 2025 | Tax withholding | −59 | $4.06 | $240 | 915 |
| Mark Oldakowski Chief Operating Officer | Jun 3, 2025 | Tax withholding | −27 | $3.69 | $100 | 974 |
| R. Erik Holmlin President and CEO, Director | Jun 3, 2025 | Tax withholding | −75 | $3.69 | $277 | 1,708 |
| Alka Chaubey Chief Medical Officer | Jun 3, 2025 | Tax withholding | −24 | $3.69 | $89 | 713 |
| Jonathan V. Dixon General Counsel | Jun 3, 2025 | Tax withholding | −25 | $3.69 | $92 | 269 |
| Mark Adamchak Principal Accounting Officer | Jun 3, 2025 | Tax withholding | −7 | $3.69 | $26 | 263 |
| R. Erik Holmlin President and CEO, Director | Mar 14, 2025 | Tax withholding | −198 | $3.47 | $687 | 1,783 |
| Mark Oldakowski Chief Operating Officer | Feb 15, 2025 | Tax withholding | −20 | $5.73 | $115 | 1,001 |
| Alka Chaubey Chief Medical Officer | Feb 15, 2025 | Tax withholding | −18 | $5.73 | $103 | 737 |
| Jonathan V. Dixon General Counsel | Feb 15, 2025 | Tax withholding | −6 | $5.73 | $34 | 294 |
| Mark Adamchak Principal Accounting Officer | Feb 15, 2025 | Tax withholding | −4 | $5.73 | $23 | 270 |
| R. Erik Holmlin President and CEO, Director | Feb 15, 2025 | Tax withholding | −51 | $5.73 | $292 | 1,981 |
| Alka Chaubey Chief Medical Officer | Sep 11, 2024 | Tax withholding | −3,075 | $0.48 | $1.48K | 45,323 |
| Mark Oldakowski Chief Operating Officer | Sep 11, 2024 | Tax withholding | −3,568 | $0.48 | $1.71K | 61,283 |
| Mark Oldakowski CHIEF OPERATING OFFICER | Jun 3, 2024 | Award | +16,000 | – | – | 64,698 |
| Jonathan V. Dixon GENERAL COUNSEL | Jun 3, 2024 | Award | +14,500 | – | – | 18,025 |
| Alka Chaubey CHIEF MEDICAL OFFICER | Jun 3, 2024 | Award | +16,000 | – | – | 48,245 |
| Gulsen Kama Chief Financial Officer | Jun 3, 2024 | Award | +16,000 | – | – | 16,000 |
| R. Erik Holmlin PRESIDENT AND CEO, Director | Jun 3, 2024 | Award | +44,000 | – | – | 121,813 |
| R. Erik Holmlin PRESIDENT AND CEO, Director | Feb 15, 2024 | Tax withholding | −3,073 | $1.27 | $3.90K | 77,663 |
| Jonathan V. Dixon GENERAL COUNSEL | Feb 15, 2024 | Tax withholding | −402 | $1.27 | $511 | 3,525 |
| Alka Chaubey CHIEF MEDICAL OFFICER | Feb 15, 2024 | Tax withholding | −1,081 | $1.27 | $1.37K | 31,487 |
| Mark Oldakowski CHIEF OPERATING OFFICER | Feb 15, 2024 | Tax withholding | −1,229 | $1.27 | $1.56K | 48,644 |
| Alka Chaubey Chief Medical Officer | Sep 18, 2023 | Award | +20,000 | – | – | 144,794 |
| Mark Oldakowski Chief Operating Officer | Sep 18, 2023 | Award | +20,000 | – | – | 317,842 |
| Hannah Mamuszka Director | Jun 13, 2023 | Buy | +65,789 | $0.76 | $50.00K | 65,789 |
| R. Erik Holmlin President and CEO, Director | May 16, 2023 | Buy | +15,000 | $0.64 | $9.60K | 806,474 |
| Mark Oldakowski Chief Operating Officer | May 12, 2023 | Tax withholding | −41,496 | $0.66 | $27.39K | 297,842 |
| R. Erik Holmlin President and CEO, Director | May 12, 2023 | Tax withholding | −50,141 | $0.66 | $33.09K | 791,474 |
| Christopher P. Stewart Chief Financial Officer | May 12, 2023 | Buy | +50,000 | $0.67 | $33.50K | 281,373 |
| Christopher P. Stewart Chief Financial Officer | Feb 15, 2023 | Award | +105,000 | – | – | 231,373 |
| Alka Chaubey Chief Medical Officer | Feb 15, 2023 | Award | +120,000 | – | – | 124,794 |
| R. Erik Holmlin President and CEO, Director | Feb 15, 2023 | Award | +300,000 | – | – | 841,615 |
| Mark Oldakowski Chief Operating Officer | Feb 15, 2023 | Award | +120,000 | – | – | 339,338 |
| Yvonne Linney Director | Aug 15, 2022 | Sale | −20,000 | $3.62 | $72.40K | 0 |
| Yvonne Linney Director | Aug 15, 2022 | Option exercise | +20,000 | $0.38 | $7.60K | 20,000 |
| David L. Barker Director | Jul 7, 2022 | Option exercise | +44,470 | $0.51 | $22.68K | 58,364 |
| David L. Barker Director | May 16, 2022 | Buy | +10,000 | $1.60 | $16.00K | 13,894 |
| Christopher P. Stewart Chief Financial Officer | May 13, 2022 | Option exercise | +60,000 | $0.56 | $33.60K | 121,579 |
| Mark Oldakowski Chief Operating Officer | May 12, 2022 | Tax withholding | −41,496 | $1.41 | $58.51K | 216,669 |
| R. Erik Holmlin President and CEO, Director | May 12, 2022 | Tax withholding | −50,141 | $1.41 | $70.70K | 538,556 |
| Soheil Shams Chief Informatics Officer | Dec 30, 2021 | Gift | −318,899 | – | – | 5,006,479 |
| R. Erik Holmlin President and CEO, Director | Nov 29, 2021 | Buy | +2,675 | $3.99 | $10.67K | 4,875 |
| R. Erik Holmlin President and CEO, Director | Nov 29, 2021 | Buy | +2,200 | $3.99 | $8.78K | 2,200 |
| R. Erik Holmlin President and CEO, Director | Nov 29, 2021 | Buy | +150 | $3.98 | $597 | 5,025 |
| Christopher P. Stewart Chief Financial Officer | Nov 19, 2021 | Option exercise | +22,500 | $0.56 | $12.60K | 55,500 |
| Soheil Shams Chief Informatics Officer | Oct 18, 2021 | Award | +5,325,378 | – | – | 5,325,378 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.